LCTX (STOCKS)
Lineage Cell Therapeutics, Inc.
$1.070000
-0.030000 (-2.73%)
Prev close: $1.100000
Company Information
- Exchange
- XASE
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Brian M. Culley, MBA
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $265.55M
- Employees
- 77
- P/E (TTM)
- -5.75
- P/B (TTM)
- 4.57
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
8
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-0.03 | $-0.03 | -0.0011 | -3.81% |
|
Mar 2026 (Q1)
|
$-0.03 | $-0.02 | -0.0096 | -47.06% |
|
Dec 2025 (Q4)
|
$0.00 | $-0.05 | +0.0527 | +100.00% |
|
Sep 2025 (Q3)
|
$-0.13 | $-0.03 | -0.1038 | -396.18% |
Financial Statements
| Revenues | $13.08M |
| Benefits Costs and Expenses | $50.47M |
| Costs And Expenses | $39.93M |
| Nonoperating Income/Loss | -$10.54M |
| Operating Expenses | $39.93M |
| Depreciation and Amortization | $739.00K |
| Research and Development | $20.52M |
| Other Operating Expenses | $18.68M |
| Operating Income/Loss | -$26.85M |
| Income/Loss From Continuing Operations After Tax | -$32.11M |
| Income/Loss From Continuing Operations Before Tax | -$37.39M |
| Income Tax Expense/Benefit, Deferred | -$5.28M |
| Net Income/Loss | -$32.11M |
| Net Income/Loss Attributable To Noncontrolling Interest | $155.00K |
| Net Income/Loss Attributable To Parent | -$32.26M |
| Net Income/Loss Available To Common Stockholders, Basic | -$32.26M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.14 |
| Diluted Earnings Per Share | -$0.19 |
| Basic Average Shares | 478,480,000 |
| Diluted Average Shares | 492,728,000 |
| Assets | $106.22M |
| Current Assets | $52.97M |
| Noncurrent Assets | $53.25M |
| Fixed Assets | $2.52M |
| Intangible Assets | $31.70M |
| Other Non-current Assets | $19.03M |
| Liabilities | $46.42M |
| Current Liabilities | $8.02M |
| Accounts Payable | $1.54M |
| Wages | $2.85M |
| Other Current Liabilities | $3.63M |
| Noncurrent Liabilities | $38.41M |
| Equity | $59.80M |
| Equity Attributable To Noncontrolling Interest | -$1.12M |
| Equity Attributable To Parent | $60.92M |
| Liabilities And Equity | $106.22M |
| Net Cash Flow From Operating Activities | -$23.82M |
| Net Cash Flow From Operating Activities, Continuing | -$23.82M |
| Net Cash Flow From Investing Activities | -$13.71M |
| Net Cash Flow From Investing Activities, Continuing | -$13.71M |
| Net Cash Flow From Financing Activities | $32.24M |
| Net Cash Flow From Financing Activities, Continuing | $32.24M |
| Exchange Gains/Losses | $430.00K |
| Net Cash Flow | -$4.86M |
| Net Cash Flow, Continuing | -$5.29M |
| Comprehensive Income/Loss | -$32.48M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $155.00K |
| Comprehensive Income/Loss Attributable To Parent | -$32.64M |
| Other Comprehensive Income/Loss | -$375.00K |